uniQure (QURE) closed at $23.87 on Nov 3, 2026, up 3.9% on the day. The stock is up 4.7% over the past month, down 46.0% over three months, down 0.3% year to date and down 30.4% over the past year (since Nov 3, 2025). It trades 53.8% below its 52-week high of $51.72 and 173.4% above its 52-week low of $8.73. The close sits below its 50-day moving average ($33.57) and below its 200-day moving average ($29.66).
QURE is scheduled to report earnings on Nov 4, 2026.
uniQure is scheduled to report on Nov 4, 2026.
No — the Nov 3, 2026 close of $23.87 is 19.5% below the 200-day average of $29.66.
QURE closed 53.8% below its 52-week high of $51.72.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
